CO2021017154A2 - Profármacos de moduladores del receptor de nmda campo de la invención - Google Patents

Profármacos de moduladores del receptor de nmda campo de la invención

Info

Publication number
CO2021017154A2
CO2021017154A2 CONC2021/0017154A CO2021017154A CO2021017154A2 CO 2021017154 A2 CO2021017154 A2 CO 2021017154A2 CO 2021017154 A CO2021017154 A CO 2021017154A CO 2021017154 A2 CO2021017154 A2 CO 2021017154A2
Authority
CO
Colombia
Prior art keywords
nmda receptor
receptor modulator
prodrugs
prodrugs field
field
Prior art date
Application number
CONC2021/0017154A
Other languages
English (en)
Inventor
Mauro Marigo
John Paul Kilburn
Erhad Ascic
Laurent David
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CO2021017154A2 publication Critical patent/CO2021017154A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a profármacos novedosos de moduladores del receptor de NMDA de fórmula I. Otros aspectos de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.
CONC2021/0017154A 2019-07-03 2021-12-15 Profármacos de moduladores del receptor de nmda campo de la invención CO2021017154A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201900822 2019-07-03
PCT/EP2020/068513 WO2021001420A1 (en) 2019-07-03 2020-07-01 Prodrugs of modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
CO2021017154A2 true CO2021017154A2 (es) 2022-01-17

Family

ID=71614856

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017154A CO2021017154A2 (es) 2019-07-03 2021-12-15 Profármacos de moduladores del receptor de nmda campo de la invención

Country Status (20)

Country Link
US (2) US11358971B2 (es)
EP (1) EP3994140A1 (es)
JP (1) JP2022538180A (es)
KR (1) KR20220034052A (es)
CN (1) CN114008053A (es)
AR (1) AR119341A1 (es)
AU (1) AU2020299410A1 (es)
BR (1) BR112021003983A2 (es)
CA (1) CA3144303A1 (es)
CL (1) CL2021003534A1 (es)
CO (1) CO2021017154A2 (es)
CR (1) CR20210663A (es)
EC (1) ECSP22003599A (es)
IL (1) IL289576A (es)
JO (1) JOP20210332A1 (es)
MA (1) MA56450A (es)
MX (1) MX2021015752A (es)
PE (1) PE20220136A1 (es)
TW (1) TW202116780A (es)
WO (1) WO2021001420A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU710575B2 (en) 1994-02-08 1999-09-23 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
JP2002511835A (ja) 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
JP5852664B2 (ja) * 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298809B (zh) * 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP3386591B1 (en) * 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
US11274107B2 (en) * 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Also Published As

Publication number Publication date
CN114008053A (zh) 2022-02-01
CR20210663A (es) 2022-02-22
CA3144303A1 (en) 2021-01-07
MX2021015752A (es) 2022-01-27
IL289576A (en) 2022-03-01
ECSP22003599A (es) 2022-02-25
AR119341A1 (es) 2021-12-09
MA56450A (fr) 2022-05-11
CL2021003534A1 (es) 2022-08-19
KR20220034052A (ko) 2022-03-17
TW202116780A (zh) 2021-05-01
US20210047342A1 (en) 2021-02-18
JOP20210332A1 (ar) 2023-01-30
PE20220136A1 (es) 2022-01-27
US11358971B2 (en) 2022-06-14
US20220213117A1 (en) 2022-07-07
AU2020299410A1 (en) 2022-02-03
JP2022538180A (ja) 2022-08-31
EP3994140A1 (en) 2022-05-11
BR112021003983A2 (pt) 2022-03-15
WO2021001420A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CU20210080A7 (es) Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa
BR112021021703A2 (pt) Cicloalquilas substituídas como moduladores da via de estresse integrada
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CO2017012545A2 (es) Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ)
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
DOP2017000117A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CR20130415A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CO2018013240A2 (es) Oligonucleótidos antisentido para modular la expresión de htra1
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
CL2019003275A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
ECSP20067907A (es) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
CO2021017154A2 (es) Profármacos de moduladores del receptor de nmda campo de la invención
ECSP22003596A (es) Moduladores del receptor de nmda
UY38304A (es) Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen
CO2021001174A2 (es) Inhibidores de ckd8/19
BR112017006613A2 (pt) composição herbicida e processo da mesma
DOP2022000026A (es) Derivados de alcohol como abridores del canal de potasio kv7
CL2023001608A1 (es) Moduladores de progranulina y métodos de uso de los mismos
CL2022002986A1 (es) Compuestos derivados de azetidina-3-ilmetanol como moduladores del receptor ccr6